Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11046-022-00655-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Understanding Microemulsions and Nanoemulsions in (Trans)Dermal Delivery.
AAPS PharmSciTech
January 2025
Consulting, Fort Collins, Colorado, USA.
Continuously explored in pharmaceuticals, microemulsions and nanoemulsions offer drug delivery opportunities that are too significant to ignore, namely safe delivery of clinically relevant drug doses across biological membranes. Their effectiveness as drug vehicles in mucosal and (trans)dermal delivery is evident from the volume of published literature. Commonly, their ability to enhance skin permeation is attributed to dispersion size, a characteristic closely related to solubilization capacity.
View Article and Find Full Text PDFInvestigation of the anti-aging effects of active components of Artemia franciscana loaded in hyalurosome.
Sci Rep
January 2025
Department of Bioprocess Engineering, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran, Iran.
With the advancement of biotechnology in the marine industry, an increasing utilization of marine ingredients in skincare products has been observed in recent years. Encapsulating Artemia franciscana extract and its derivatives in a novel phospholipid vesicle called hyalurosome presents innovative strategies for drug delivery systems and anti-aging products. In this study, we developed nano hyalurosomes containing Artemia franciscana active components.
View Article and Find Full Text PDFNanocrystals in Dermal Drug Delivery: A Breakthrough for Enhanced Skin Penetration and Targeted Skin Disorder Treatments.
Pharmaceutics
December 2024
Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia.
One of the major challenges in dermal drug delivery is the adequate penetration of the active compound into the skin without causing any skin irritation and inflammation. Nanocrystals (NCs) are nanoscale particles, and their sizes are below 1000 nm. NCs are made up of drug particles only, which are used to improve the aqueous solubility and bioavailability of poorly water-soluble drugs.
View Article and Find Full Text PDFExtrapulmonary Sarcoidosis Presenting as Bilateral Lower Limb Erythema Nodosum Triggered by Intradermal Fillers: A Case of Misdiagnosis As Soft-Tissue Infection.
Cureus
December 2024
Department of Medicine, MetroWest Medical Center, Framingham, USA.
Localized inflammatory reactions in patients with past procedural history of intradermal injections can quickly drive the clinician's attention towards a diagnosis of soft-tissue infection in the context of symptoms such as fever, malaise, and local induration of the adipose panniculus. However, in patients with a long-term history of granulomatous events, a rheumatologic approach must be taken into consideration when the clinical course overwhelms the odds for more conventional diagnoses. In this case, a 39-year-old female patient who underwent bilateral lower limbs intradermal filllers presented with a two-year clinical course of repetitive flares of external bilateral hip tenderness, pain that limits her walking, soft-tissue nodular inflammation, redness, fever and a soft mobile nonpainful right supraclavicular lymphadenopathy.
View Article and Find Full Text PDFPilot study of topical ruxolitinib demonstrates efficacy and blunting of heterogeneous inflammatory processes in mild hidradenitis suppurativa.
Br J Dermatol
December 2024
The Pennsylvania State University College of Medicine, Department of Dermatology, Hershey, PA, USA.
Background: Therapeutic options for mild hidradenitis suppurativa (HS) represent a significant gap in the current treatment landscape, with no FDA approved therapies for early stage HS. Topical JAnus Kinase inhibitors (JAKi) are a compelling option due to the known upregulation of inflammatory JAK signaling in HS lesions and the recent success of systemic JAKi for moderate to severe HS.
Objectives: This is a pilot, single-site, open-label, prospective 24-week clinical trial with topical ruxolitinib (NCT04414514).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!